The RGTA® Technology
Our technology, based on ReGeneraTing Agents (RGTA®), helps restore the cellular microenvironment to maximize tissue regeneration.
Our Research & Development
OTR3 is a biotechnology company with a strong focus on the development of matrix therapy. The quality of its research is recognized by the European Commission (through the H2020 SME Instrument), the French National Research Agency (ANR), and the Île-de-France Region through multiple ongoing research and development programs.
Our commercial Activity
ISO 13485–certified, OTR3 markets its products internationally as human medical devices and veterinary comfort products across Europe, South America, North America, the Middle East, and Asia.





